Sirolimus (Rapamune)

DRUG4 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, St. Joseph's Healthcare Hamilton, West China Hospital

Conditions

Graft vs Host DiseaseKidney TransplantationLiver TransplantationLymphatic MalformationProstate Cancer

Phase 2

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

WithdrawnNCT00922129

St. Joseph's Healthcare HamiltonProstate Cancer

Start: 2009-09-30End: 2011-01-31Updated: 2014-01-14

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

RecruitingNCT06673290

West China HospitalLymphatic Malformation

Start: 2024-11-30End: 2026-12-30Target: 150Updated: 2024-12-31

Phase 3

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

CompletedNCT00037531

Wyeth is now a wholly owned subsidiary of PfizerGraft vs Host Disease, Kidney Transplantation

End: 2004-08-31Updated: 2009-08-18

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

TerminatedNCT00086346

Wyeth is now a wholly owned subsidiary of PfizerLiver Transplantation

Start: 2002-12-31End: 2008-07-31Updated: 2010-04-28